

# **COVID-19 Testing among Deceased Persons** Undergoing Verbal Autopsy — University Teaching Hospital, Zambia, **April 2020–August 2021** Priscilla Kapombe

24 May 2023

# 21 bodies brought in Dead due to COVID-19 in the last 24 hours



 ORDERT
 D JUNE 21, 2021
 Ø 0
 Ø 1.5K
 № 0
 Ø 0



# <section-header>

Advertise Here

Zambia has recorded a total of twenty-three COVID-19 related deaths in the last 24hrs. Out of the 23 deaths, 21 were brought in dead (BIDs) and two were facility deaths.



# Introduction

- Zambia experienced a COVID-19 epidemic, with >340,000 confirmed cases and >4,000 deaths through April 2023
- The number of deaths is likely an underestimate because:
  - Testing limitations, especially early in the pandemic
  - A large proportion (30-50%) of people die in the community in Zambia
  - Limited medical services during waves, especially the delta wave (i.e., Jun/Jul 2021)
- Assessing the toll of COVID-19 on the country might inform public health and clinical actions for COVID-19 and future potential pandemic threats in Zambia



# Methods – Study Setting

- Cross-sectional study of deceased persons at University Teaching Hospital (UTH) in Lusaka
  - UTH is a tertiary care center / referral hospital for entire country
- In Zambia, VAs are done for deceased persons who died in the community or within 48hrs of admission \*
  - (VA mortality surveillance done in 25 districts in Zambia, including Lusaka)
  - An MCCD form is completed by the attending clinician on in-patient deaths that occur ≥48hrs of admission
- UTH Mortuary accepts community deaths for most (~90%) of Lusaka District
  - A burial permit is required for funerals within Lusaka District
  - Proof of a verbal autopsy (VA) or MCCD form is required to obtain a burial permit



# Methods – Data Collection

- A WHO questionnaire is administered by trained surveillance officers
  - InterVA5 software analyzes WHO VA questionnaire responses to output a probable underlying cause of death (COD)
- UTH mortuary did COVID-19 testing on deceased person
  - PCR and RDT tests
  - When supplies were available





# Methods – Data Analysis

- Analyzed deceased person with both a VA and COVID test results
  - Underlying COD by COVID test result status (positive vs. negative)
  - Other VA questions (i.e., symptoms, comorbidities) by COVID test result status
  - Factors associated with testing COVID-19 positive estimated using logistic regression
- Data in this analysis cover April 2020 to August 2021
  - VA questions on antemortem COVID diagnosis/testing added to questionnaire in October 2020



# Sample Size

- 12,919 deceased persons
   BID during April 2020 to
   August 2021
- 5,555 (43.0%) had both a
   VA and COVID-19 test
- 422 (4.6%) were COVID-19 positive





# COVID-19 Positivity by VA Status

	All deceased person tested, n (%) (N = 9,147)	All deceased person tested, n (%) (N = 9,147) Had a VA done, n (%) (N = 5,555)		p-value
Tested COVID-19 positive	422 (4.6)	278 (5.0)	144 (4.0)	0.04
VA: Verbal autopsy				



# VA and COVID Test Coverage by Month

Sample size of deceased persons with VA and COVID test by month at UTH, Apr 2020 to Aug 2021





# Patient Characteristics and Circumstances of Death

Characteristic	Overall, n (%) N = 5,555	Positive, n (%) N = 278	Negative, n (%) N = 5,277	Odds ratio (95% CI)
Sex				
Male	3,282 (59.1)	163 (58.6)	3,119 (59.1)	Ref.
Female	2,273 (40.9)	115 (41.4)	2,158 (40.9)	1.0 (0.8-1.3)
Age group				
0-17	765 (13.8)	13 (4.7)	752 (14.3)	Ref.
18-49	2,374 (42.7)	87 (31.3)	2,287 (43.3)	2.2 (1.2-4.0)
≥50	2,416 (43.5)	178 (64.0)	2,238 (42.4)	<mark>4.6</mark> (2.6-8.1)
HIV positive	1,184 (21.3)	67 (24.1)	1,117 (21.2)	1.2 (0.9-1.5)
Place of death (n miss = 9)				
Home	4,421 (79.6)	222 (79.9)	4,199 (79.6)	Ref.
Health facility	1,123 (20.2)	55 (19.8)	1,068 (20.2)	1.0 (0.7-1.3)
Died during a COVID wave period*	3,511 (63.2)	250 (89.9)	3,261 (61.8)	<mark>5.5</mark> (3.7-8.2)
Died suddenly <sup>+</sup>	1,451 (26.1)	61 (21.9)	1,390 (26.3)	0.8 (0.6-1.1)
Received care before death <sup>‡</sup>	3,724 (67.0)	185 (66.5)	3,539 (67.1)	1.0 (0.8-1.3)
Tested for COVID-19 antemortem <sup>¶</sup>	1,854 (33.4)	97 (34.9)	1,757 (33.3)	3.7 (2.5-5.4)

\* Wave period defined as Jun 30 to Sep 21, 2020 (wildtype/wave 1), Jan 3-Mar 19, 2021 (beta/wave 2), and May 28-Aug 22, 2021 (delta/wave 3)

<sup>+</sup> A sudden death was defined as dying within 24 hours of being in regular/good health

‡ Indicates person received care for the condition that led to death

¶ Questions about antemortem COVID-19 testing not added to VA until October 2020 (observations in logistic regression were 4,074)



# Causes of Death by COVID-19 Status\*

### COVID-19 test positive (N = 278)

Rank	Probable cause of death	n (%)
1	Acute cardiac disease	51 (18.3)
2	Respiratory tract infections/pneumonia	46 (16.5)
3	Other/unspecified cardiac disease	36 (12.9)
4	Stroke	20 (7.2)
5	HIV/AIDS related death	17 (6.1)
6	Pulmonary tuberculosis	16 (5.8)
7	Diabetes mellitus	14 (5.0)
8	Diarrheal diseases	11 (4.0)
9	Digestive neoplasms	8 (2.9)
10	Indeterminate	7 (2.5)

### *COVID-19 test negative* (*N* = 5,277)

Rank	Probable cause of death	n (%)
1	Acute cardiac disease	646 (12.2)
2	HIV/AIDS related death	562 (10.6)
3	Other/unspecified cardiac disease	560 (10.6)
4	Stroke	469 (8.9)
5	Respiratory tract infections/pneumonia	413 (7.8)
6	Diarrheal diseases	288 (5.5)
7	Pulmonary tuberculosis	271 (5.1)
8	Indeterminate	227 (4.3)
9	Digestive neoplasms	222 (4.2)
10	Diabetes mellitus	190 (3.6)



# Symptoms Prior to Death

Symptoms	Positive, n (%) N = 278	Negative, n (%) N = 5,277	Odds ratio (95% CI)	p-value
Fever	111 (39.9)	1,791 (33.9)	1.3 (1.0-1.7)	0.04
Cough	125 (45.0)	1,783 (33.8)	1.6 (1.3-2.0)	< 0.01
Shortness of breath	142 (51.1)	2,171 (41.1)	1.5 (1.2-1.9)	<0.01
Tachypnea	72 (25.9)	1,123 (21.3)	1.3 (1.0-1.7)	0.07
Chest pain	88 (31.7)	1,353 (25.6)	1.3 (1.0-1.7)	0.04
Headache	90 (32.4)	1,524 (28.9)	1.2 (0.9-1.5)	0.29
Classic covid symptoms*	201 (72.3)	3247 (61.5)	1.6 (1.3-2.1)	< 0.01
Asymptomatic <sup>+</sup>	44 (15.8)	1,135 (21.5)	0.7 (0.5-1.0)	0.03

\* Defined as fever, cough, or shortness of breath

<sup>+</sup> Defined as an absence of any of the following: fever, cough, shortness or breath, tachypnea, chest pain, headache, diarrhea, vomiting, abdominal pain, rash, of mental confusion



# Antemortem COVID-19 Diagnosis/Testing

- In total, 1,850 (42.9%) deceased persons were reportedly tested for COVID prior to death (i.e., antemortem) from Oct 2020 to Aug 2021
- 201 (10.9%) were reportedly COVID-19 positive
  - Most (90.5%) who reported testing positive were diagnosed with COVID-19 by an HCW





# Antemortem and Postmortem COVID Results

- 97 (73.5%) of deceased persons who tested positive at UTH had been tested for COVID prior to death
  - Of these, 64 (66.0%) were reportedly
     COVID positive
- Of 201 who reported testing positive, 64 (31.8%) tested covid positive postmortem
  - Odds of testing COVID positive postmortem if reporting COVID test positive antemortem were 22.2 (95% CI: 14.0-35.1)



Analysis restricted to October 2020 to August 2021

\* One person with antemortem test but no result tested COVID positive postmortem (not shown)



# Diagnostic Accuracy of COVID-19 History prior to Death

- Antemortem COVID diagnosis by a HCW and positive COVID test results had low sensitivity but moderate specificity for testing COVID positive after death
- Negative predictive value was high of antemortem COVID diagnosis and test results

		COVID test postmortem		
		(+)	(-)	
COVID <b>diagnosis</b>	(+)	66	528	
antemortem	(-)	66	3,555	
Se: 0.50 PPV: 0.1 Sp: 0.87 NPV: 0.9	1 8			





# Limitations

- Findings reflect experience from a large tertiary referral hospital in a capital city. Generalizability of findings in other parts of Zambia is not known
- Not all deceased persons at UTH were tested because of inconsistent supply of testing kits/reagents
- Unable to distinguish between PCR and RDT tests (data not collected)
- Timing of antemortem COVID-19 test results was not collected
- Timing of postmortem COVID-19 testing and COVID-19 assay test properties could affect findings
  - Deceased persons with COVID-19 might no longer be shedding virus by the time of postmortem testing
  - RDTs can result in false negatives. PCR tests can result in false positive (from crosscontamination)
- InterVA5-coded COD is considered probable



# Discussion (1)

- A notable portion of deceased persons from the community or recently admitted tested COVID-19 positive during the wild-type and delta waves in Zambia
  - However, few tested COVID-19 positive during the beta wave
- Only a minority persons testing COVID-19 positive at deaths were coded as respiratory tract infections
  - Cardiac disease and stroke CODs might reflect sequelae of the hypercoagulable state described with severe COVID-19
- Most persons testing COVID-19 positive postmortem reportedly displayed classic symptoms and were tested before dying
  - This could indicate a strained medical system during COVID-19 waves in Zambia



# Discussion (2)

- Overall findings generally align with another concurrent COVID-19 postmortem study at UTH
  - This study demonstrated much lower percent positivity of deceased persons and greater antemortem diagnosis and COVID-19 testing coverage
  - Many more persons tested in this study (5,555 vs. 1,118)
  - Potential reasons for differences include different testing approaches, unmeasured bias in either study's recruitment, the period of testing cover a larger non wave period (summer) hence proportion of positivity is lower.



# Recommendations

- Enhancing mortality surveillance during outbreaks can provide useful information to inform public health and clinical care
  - However, relying on respiratory COD from VA as surrogate for COVID-19 deaths might underestimate true burden. This points to the value of also measuring all-cause mortality
- Improved availability of antivirals, anticoagulants, and other therapeutics might avert mortality during future waves in Zambia
- Low sensitivity of antemortem COVID-19 history points to value of postmortem surveillance



# Way-Forward

- In an effort to enhance and ensure a coordinated mortality surveillance system that enables timely collection, processing, analysis and dissemination of quality data; following lessons learnt from Covid-19:
  - Stakeholder buy in (reviving of a Technical Committee focusing on MS MSSC).
  - Political will/support following launch of the African Continental Framework in Zambia.
  - Guiding Document (As a country, adopted the Africa CDC Continental Framework for Strengthening Mortality Surveillance Systems).



# Steps Taken

- Mortality Surveillance Subcommittee has held monthly meetings from the launch.
- Undertook a comprehensive stakeholder mapping workshop with support from the Africa CDC Regional Coordinating Committee.
- Conducting national MS assessment.
- Initiated phase 1 of drafting the national strategic action plan (process guided by the framework and supported by A-CDC).
- Planning for implementation of Sample Registration System are underway.



# **Study Collaborators**

- Zambia Ministry of Health
  - Mweene Cheelo
  - Lloyd B. Mulenga
  - Patrick Lungu
- University Teaching Hospital Mortuary/Ministry of Home Affairs (National Forensic Authority)
  - Adam Mucheleng'anga

- Zambia National Public Health Institute
  - Stephen L. Chanda
  - Amos Hamukale
- U.S. Centers for Disease Control and Prevention
  - Jonas Z. Hines
  - Kashala Kamalonga
  - Leigh Tally
  - Andrew F. Auld